Nothing Special   »   [go: up one dir, main page]

EA201691426A1 - Регулирование метаболизма орнитина для управления содержанием высокоманнозных гликоформ рекомбинантных белков - Google Patents

Регулирование метаболизма орнитина для управления содержанием высокоманнозных гликоформ рекомбинантных белков

Info

Publication number
EA201691426A1
EA201691426A1 EA201691426A EA201691426A EA201691426A1 EA 201691426 A1 EA201691426 A1 EA 201691426A1 EA 201691426 A EA201691426 A EA 201691426A EA 201691426 A EA201691426 A EA 201691426A EA 201691426 A1 EA201691426 A1 EA 201691426A1
Authority
EA
Eurasian Patent Office
Prior art keywords
content
glyforms
ornitin
metabolism
regulation
Prior art date
Application number
EA201691426A
Other languages
English (en)
Other versions
EA039141B1 (ru
Inventor
Сохие Канг
Чунг-Мл Хуанг
Хедье Бархордарьян
Павел Бондаренко
Чжунци Чжан
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52273554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201691426(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA201691426A1 publication Critical patent/EA201691426A1/ru
Publication of EA039141B1 publication Critical patent/EA039141B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0681Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/32Amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/32Amino acids
    • C12N2500/33Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/46Amines, e.g. putrescine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/90Serum-free medium, which may still contain naturally-sourced components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/99Serum-free medium
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70Enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70Enzymes
    • C12N2501/72Transferases [EC 2.]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70Enzymes
    • C12N2501/73Hydrolases (EC 3.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999Small molecules not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00Culture process characterised by the use of hydrostatic pressure, flow or shear forces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение обеспечивает способ управления содержанием высокоманнозных гликоформ рекомбинантных гликопротеинов путем регулирования метаболизма орнитина в процессе культивирования клеток.
EA201691426A 2014-01-13 2014-12-09 Рекомбинантный белок с пониженным содержанием высокоманнозных гликоформ, способ его получения и применение EA039141B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461926481P 2014-01-13 2014-01-13
PCT/US2014/069378 WO2015105609A1 (en) 2014-01-13 2014-12-09 Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins

Publications (2)

Publication Number Publication Date
EA201691426A1 true EA201691426A1 (ru) 2016-11-30
EA039141B1 EA039141B1 (ru) 2021-12-09

Family

ID=52273554

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201691426A EA039141B1 (ru) 2014-01-13 2014-12-09 Рекомбинантный белок с пониженным содержанием высокоманнозных гликоформ, способ его получения и применение
EA202191909A EA202191909A1 (ru) 2014-01-13 2014-12-09 Регулирование метаболизма орнитина для управления содержанием высокоманнозных гликоформ рекомбинантных белков

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202191909A EA202191909A1 (ru) 2014-01-13 2014-12-09 Регулирование метаболизма орнитина для управления содержанием высокоманнозных гликоформ рекомбинантных белков

Country Status (14)

Country Link
US (2) US10513723B2 (ru)
EP (1) EP3094735A1 (ru)
JP (1) JP6732660B2 (ru)
KR (1) KR102381791B1 (ru)
CN (2) CN106029896B (ru)
AU (3) AU2014376225C1 (ru)
BR (2) BR122020004385B1 (ru)
CA (1) CA2936104C (ru)
CL (3) CL2016001786A1 (ru)
EA (2) EA039141B1 (ru)
IL (1) IL246727B (ru)
MX (1) MX2016009084A (ru)
SG (2) SG10201806643WA (ru)
WO (1) WO2015105609A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CN114075269A (zh) * 2017-07-06 2022-02-22 菲仕兰坎皮纳荷兰私人有限公司 用于制备糖蛋白的细胞培养工艺
RU2672318C1 (ru) * 2017-09-19 2018-11-13 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Способ получения моноклональных антител терапевтического назначения с помощью непрерывного культивирования клеток сно
US11566062B2 (en) 2017-12-20 2023-01-31 Ares Trading S.A. Methods for modulating protein mannosylation profiles using maduramycin, narasin, or salinomycin
CN111671051B (zh) * 2020-07-30 2022-01-11 广州同康生物科技有限公司 一种整粒黄豆中嘌呤的脱除工艺

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DK0417563T3 (da) 1989-09-12 2000-11-06 Hoffmann La Roche TNF-bindende proteiner
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
EP0672141B1 (en) 1992-10-23 2003-05-14 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
DE69635480T2 (de) 1995-06-29 2006-08-17 Immunex Corp., Thousand Oaks Apoptosis induzierendes cytokin
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
AR031699A1 (es) 2000-05-26 2003-10-01 Bristol Myers Squibb Co Molecula mutante de ctla4 soluble que se enlaza a cd80 y/o cd86, molecula de acido nucleico que la codifica, vector y sistema vector que comprende a esta ultima, celula huesped que lo posee, metodo para producir una proteina mutante y dicha proteina, uso de la molecula mutante para preparar un medic
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
US20100221823A1 (en) * 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
HUE033279T2 (en) 2011-07-01 2017-11-28 Amgen Inc Mammalian cell culture

Also Published As

Publication number Publication date
JP2017501749A (ja) 2017-01-19
BR112016015797B1 (pt) 2022-10-11
WO2015105609A1 (en) 2015-07-16
SG10201806643WA (en) 2018-09-27
IL246727A0 (en) 2016-08-31
IL246727B (en) 2020-05-31
US20200071738A1 (en) 2020-03-05
AU2014376225B2 (en) 2018-06-07
CL2018002548A1 (es) 2018-10-26
AU2018226416A1 (en) 2018-09-27
CN106029896B (zh) 2020-10-27
JP6732660B2 (ja) 2020-07-29
MX2016009084A (es) 2016-10-13
US20160333385A1 (en) 2016-11-17
BR112016015797A2 (ru) 2017-10-03
AU2014376225C1 (en) 2019-02-21
US11254963B2 (en) 2022-02-22
AU2014376225A1 (en) 2016-07-21
CL2016001786A1 (es) 2017-06-02
EA039141B1 (ru) 2021-12-09
CN106029896A (zh) 2016-10-12
CN112481337A (zh) 2021-03-12
BR122020004385B1 (pt) 2022-10-04
CL2022000470A1 (es) 2022-10-21
CA2936104C (en) 2022-04-19
KR20160104073A (ko) 2016-09-02
CN112481337B (zh) 2024-06-25
EA202191909A1 (ru) 2022-01-31
AU2018226416B2 (en) 2020-08-27
KR102381791B1 (ko) 2022-03-31
AU2020260443B2 (en) 2022-10-27
AU2020260443A1 (en) 2020-11-26
SG11201605640UA (en) 2016-08-30
EP3094735A1 (en) 2016-11-23
US10513723B2 (en) 2019-12-24
CA2936104A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
EA202091598A3 (ru) Процесс контроля уровня содержания гликанов в составе
IL284796A (en) Control of gene expression through aptamer-mediated modulation of alternative splicing
EA201691426A1 (ru) Регулирование метаболизма орнитина для управления содержанием высокоманнозных гликоформ рекомбинантных белков
MX2018016258A (es) Metodo de diferenciacion mejorada.
EA201301102A1 (ru) Композиция для регуляции роста растений
EP3119200A4 (en) Plant disease control composition and method for controlling plant disease by application of same
EP3697911A4 (en) GENE EXPRESSION REGULATION PROCESS
MX2016009848A (es) Método de modulación de la galactosilación de proteína recombinante mediante optimización de medio de cultivo.
MY180732A (en) Protein manufacture
IL258633B (en) System and method for regulating the production of biological materials based on cell culture
IL269197A (en) Control of fully apocosylated antibody glycoforms produced in cell culture
EP3321759A4 (en) Flow control method for proportional valve of breathing machine
MX2020012356A (es) Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes.
MY165602A (en) Engine controller and engine control method
HUE058103T2 (hu) Saját közegszabályozású szabályozó szelep
MX2016015615A (es) Control de la formacion de enlaces disulfuro en disoluciones de proteinas mediante la adicion de agentes reductores.
EP3366776A4 (en) RECOMBINANT MICROORGANISM FOR THE PRODUCTION OF L-THREONIN AND PROCESS FOR PRODUCING L-THREONIN USING THE SAME
EA201790360A1 (ru) Получение полностью процессированного и функционального фактора x в фурин-секретирующей системе экспрессии млекопитающего
EP3354722A4 (en) METHOD FOR CONTROLLING THE DIFFERENTIATION OF STEM CELLS
MX2016011280A (es) Composicion conteniendo cianamida emulsificable o auto-emulsificable.
AU2015242879A1 (en) Melatonin secretion regulator, and method for regulating melatonin secretion
UA111356C2 (uk) Композиція для регуляції росту рослин
BR112017014252A2 (pt) método para o controle de glicosilação de glicoproteína recombinante
MY150764A (en) Method for controlling termite pest
TH170872A (th) วิธีการสำหรับการควบคุมไกลโคซีเลชั่น (glycosylation) ของรีคอมบิแนนท์ไกลโคโปรตีน (recombinant glycoprotein)